Excorp Medical

The artificial bio-liver system, jointly developed over a decade by Excorp Medical, Inc. and the Thomas E. Starzl Organ Transplantation Institute at the University of Pittsburgh, renowned for liver transplantation and bio-tissue engineering, has completed Phase I and II clinical trials as required by the U.S. Food and Drug Administration (FDA). The feasibility, safety, and efficacy of its clinical application have been fully affirmed.